Tideglusib (NP-12, NP031112) is a potent and irreversible small molecule glycogen synthase kinase 3 (GSK-3) inhibitor.
Tideglusib (NP-12, NP031112) is a potent and irreversible small molecule glycogen synthase kinase 3 (GSK-3) inhibitor.
== Clinical trials == Tideglusib has been evaluated in clinical trials for: Alzheimer's disease and progressive supranuclear palsy. Both clinical trials were discontinued in 2011 (PSP) and 2012 (Alzheimer's disease) due to lack of efficacy Congenital/juvenile-onset myotonic muscular dystrophy type I.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).